Navigation Links
Targeted drug therapy prevents exercise-induced arrhythmias
Date:3/29/2009

de calcium-handling proteins, the ryanodine receptor and calsequestrin, cause the disorder.

In 2006, the group discovered how these mutations cause arrhythmias at the cellular level by allowing calcium to "leak" out of its storage containers inside heart cells. Knollmann's team developed a mouse model for CPVT (by eliminating the calsequestrin gene) and proposed using the model to study medications and interventions for the disorder.

They tried flecainide, a clinically available anti-arrhythmic that is used to treat atrial fibrillation. It worked.

In isolated heart cells, flecainide blocked the ryanodine receptor and the calcium "leak" (the underlying molecular defect in CPVT), and it completely prevented ventricular arrhythmias in the mouse model of CPVT.

"So we knew that this established drug specifically targets the disease mechanism in CPVT," Knollmann said.

With these encouraging results, the investigators teamed with Arthur Wilde, M.D., Ph.D., at the University of Amsterdam, to test flecainide in two patients with CPVT who continued to have arrhythmias while on conventional therapies the previously mentioned 12-year-old boy and a 36-year-old woman. The boy has a mutation in the calsequestrin gene, the same gene mutated in the mouse model; the woman has a mutation in the ryanodine receptor, which is more common among CPVT patients.

In both patients, flecainide (combined with a beta blocker in the boy) prevented exercise-induced ventricular arrhythmias. The patients have taken flecainide for more than six months now and are living normal lives.

The group is currently enrolling additional CPVT patients to clearly define the benefits and risks of flecainide and to compare how it works in patients who have varying ryanodine receptor and calsequestrin mutations.

Frank Fish, M.D., a pediatric cardiologist at Vanderbilt, has placed two patients with CPVT on flecainide therapy.

"We're hoping that
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
2. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
3. Researchers combat slowing yields with targeted fertilizer applications
4. Fishing throws targeted species off balance, Scripps study shows
5. New technique allows targeted inactivation of genes in research model
6. Newly identified role for power plants in human cells could lead to targeted therapies
7. Consortium develops new method enabling routine targeted gene modification
8. On the trail of a targeted therapy for blood cancers
9. Cellular discovery may lead to targeted treatment for rare form of anemia
10. Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... pulp is wood. However, growing demand in the paper industry, ... sector to turn to other sources of raw materials, such ... This residue, obtained after crushing of the cane, is already ... (in South America and India for example, where it represents ...
... first biochemical marker linked to sleep loss, an enzyme in ... deprivation is prolonged. , Researchers hope to make amylase the ... and treatment of sleep disorders and may one day help ... a car or in other dangerous contexts. , ...
... Lee Dequeant, Ph.D., a Predoctoral Researcher at the Stowers ... Institute Investigator and an investigator with the Howard Hughes ... on a paper that identifies a network of cyclic ... spine formation in the embryo. , The ...
Cached Biology News:Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry 2Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry 3First biomarker for human sleepiness identified in fruit flies 2First biomarker for human sleepiness identified in fruit flies 3
(Date:3/6/2015)... According to a new market research report ... Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) by Application ... Global Forecast to 2019", published by MarketsandMarkets, the Soft ... in 2019 from $10.3 Billion in 2014, at a ... Browse 70 market data tables and 32 ...
(Date:3/6/2015)... , March 6, 2015   Senomyx , Inc. ... proprietary taste science technologies to discover, develop, and commercialize ... industries, announced today that John Poyhonen , the Company,s ... , Senior Vice President and Chief Financial Officer, will ... scheduled for Wednesday, March 11, at 2:00 p.m. Eastern ...
(Date:3/5/2015)... YORK , March 5, 2015  DuPont (NYSE: ... Morgan Aviation, Transportation and Industrials Conference held today in ... President Matthew L. Trerotola discussed strategy, progress ... Materials segments for DuPont.  Strengthening and growing the company,s ... the three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... Altamonte Springs, FL (PRWEB) March 05, 2015 ... Jamie Damm for the position of Vice President of ... support managed care relationships for one of the nation’s ... Seattle, brings more than 15 years of specialty pharmacy ... Previously Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... Delivers Solid Financial Performance While Building for the Future, ... GENZ ) today reported strong sales and profit growth ... commercial and clinical,programs., Revenue increased 25 percent to ... quarter. The increase was driven by,growth across all areas ...
... TORONTO, July 23 /PRNewswire-FirstCall/ - Roche,(SWX: ROG) and ... two,companies have signed a definitive agreement for Roche ... price of approximately C$191 million. ARIUS is,the developer ... identifies and selects antibodies based on their functional,ability ...
... of,Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share. The dividend will be,payable on September ... 2008.,The indicated annual dividend rate is $1.14 per share., ... medical technology company that develops,manufactures and sells medical devices, ...
Cached Biology Technology:Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 2Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 3Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics 4
Leucine-rich repeat-containing G-protein coupled receptor 4...
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... Cultured human omental preadipocytes ... but otherwise healthy donors. ... of diabetic cells. Please ... Support media also available. ...
Biology Products: